• 2020 GAPNA Pharmacology Conference: Contemporary Pharmacology and Prescribing in Older AdultsJoin us at the 2020 GAPNA Pharmacology Conference:
    Contemporary Pharmacology and Prescribing in Older Adults

    April 14-18, 2020, Honolulu, HI.

    Earn up to 18 CNE hours.


    Find out more about it and REGISTER today!

  • W A N T E D   G A P N A   L E A D E R S!
    Call for Nominations!

    Have you ever considered stepping forward, accepting the challenge and volunteering for a position on the 2020-21 National Board of Directors? Register online NOW by March 22, 2020!

    Step Up - NOW is the Time! Register Here>

  • AwardNew for GAPNA members: MCM Education

    GAPNA has partnered with a MCM Education to offer an ongoing series of CNE programs available to GAPNA members. "Diagnosing and Managing Parkinson’s Disease in Older Adults," is the latest program offered.

    Parkinson’s disease (PD) is characterized by both motor and nonmotor symptoms. It is diagnosed based on the presence of two of four motor symptoms including rest tremor, bradykinesia, rigidity, and gait imbalance...

    Find out about it!

  • ConventionCALL FOR: Podium and Poster Abstracts

    For the 38th GAPNA Annual Conference
    at the Hyatt Regency
    New Orleans, LA, September 24-26, 2020

    GAPNA members are invited to submit an abstract about their innovative work, that should enrich the APRN's knowledge and/or enhance the care of an older adult. Deadline March 15, 2020.

    Find out more info and deadline dates

  • FREE CE for GAPNA MembersFREE continuing education credit is available for the following session:

    "Update in Chronic Kidney Disease Management and Prescribing"

    (session captured at the GAPNA 2018 Annual Conference)

    For January/February 2020 - Get Your Free CNE Now!


Clinical Pearl: Parkinson’s Disease Considerations and Treatment

By Sharon Bronner

Parkinson’s disease (PD) has been reported by the Centers for Disease Control and Prevention as the 14th leading cause of death.

Prevalence increases with age, and trends of aging in the global population ensure healthcare professionals will encounter PD increasingly over the coming decades. Psychosis associated with PD most often occurs in patients who are older, who have more advanced disease, and who manifest greater cognitive impairment. Parkinson’s disease psychosis symptoms may consist of hallucinations and delusions.

The clinical definition of the main features of psychosis includes hallucinations, illusions, and delusions. The current ICD-10 guidelines define hallucinations as a disorder characterized by a false sensory perception in the absence of an external stimulus, whereas an illusion is regarded as a misperception of an externally present stimulus.

PD can be debilitating with physical and mental symptoms. The older adult may present with mobility concerns, and experience fatigue, weight loss, sleep disturbances, mood disorders, and psychosis. The prevalence of psychosis occurs with disease duration, in addition to new visual symptoms of the psychosis continuum, and identification of frontal executive, visual perceptual, and memory dysfunction at different disease stages.


Nonpharmacological treatments for PD psychosis such as reassurance and discussion with the patient are being explored but have not yet been firmly established. One of the most important considerations is to ensure the older adult does not have access to weapons. In addition, it is important to keep in mind that other acute or subacute illnesses may cause these symptoms to emerge.

An increase in symptoms may be due to a simple problem such as urinary tract infection or something more complex such as subdural hematoma. Since hallucinations tend to occur in the evening and nighttime with lower light, well-lighted rooms and a nightlight may provide some benefit. It is important to be aware of sundowning syndrome.

Pharmacological treatments for PD psychosis consist of atypical antipsychotic medications. Medications typically used to manage symptoms have included quetiapine (Seroque®) and, less commonly, clozapine. Clozapine (Clozaril®) is infrequently prescribed because of the burdensome requirement for monitoring blood counts for the small but potentially fatal risk of neutropenia. Pimavanserin (Nuplazid®) was developed specifically to treat PD psychosis by its action at serotonin receptors, a quality shared by quetiapine and clozapine. The golden rule for starting medications in older adults is start low and go slow for increasing medications.

Sharon Bronner, DNP, MSN, APRN, GNP-BC, ACHPN, Hct


  • Chang, A., & Fox, S.H. (2016). Psychosis in Parkinson’s disease: Epidemiology, pathophysiology, and management. Drugs, 76(11), 1093-1118.
  • Cummings, J., Isaacson, S., Mills, R., Williams, H., Chi-Burris, K., Corbett, A., … Ballard, C. (2014). Pimavanserin for patients with Parkinson’s disease psychosis: A randomized, placebo-controlled phase 3 trial. Lancet, 383(9916), 533-540.
  • Ffytche, D., Creese, B., Politis, M., Chaudhuri, K.R., Weintraub, D., Ballard, C., & Aarsland, D. (2017). The psychosis spectrum in Parkinson disease. Nature Reviews Neurology, 13(2), 81-95. https://doi.org/10.1038/nrneurol.2016.200
  • Hacksell, U., Burstein, E.S., McFarland, K., Mills, R.G., & Williams, H. (2014). On the discovery and development of pimavanserin: A novel drug candidate for Parkinson’s psychosis. Neurochemical Research, 39(10), 2008-2017.
  • Hermanowicz, N. (2018). Parkinson disease psychosis: Evaluation and treatment. Neurology Times. https://www.neurologytimes.com/parkinson-disease/parkinson-disease-psych...
  • Seppi, K., Weintraub, D., Coelho, M., Perez-Lloret, S., Fox, S.H., Katzenschlager, R., ... Sampaio, C. (2011). The Movement Disorder Society evidence-based medicine review update: Treatments for the non-motor symptoms of Parkinson disease. Movement Disorders, 26(Suppl. 3), S42-80.


Join your friends in Honolulu, Hawaii at the 2020 GAPNA Contemporary Pharmacology and Prescribing in Older Adults Conference on April 14-18, 2020.

Learn more and register today!